Published • loading... • Updated
D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
- D3 Bio announced that the FDA has cleared two Investigational New Drug applications for D3S‑003 and a combination study involving D3S‑001 and D3S‑002.
- The U.S. Food and Drug Administration has cleared two Investigational New Drug applications from D3 Bio.
- With this clearance, D3 Bio will start a Phase 1 trial of D3S‑003 in patients with advanced solid tumors that have KRAS G12D mutations.
- A Phase 2 study will analyze the combination of D3S‑001 and D3S‑002 in patients with KRAS G12C–mutant non‑small cell lung cancer .
Insights by Ground AI
51 Articles
51 Articles
Chatham Star Tribune+50 Reposted by 50 other sources
D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications:
Coverage Details
Total News Sources51
Leaning Left5Leaning Right4Center35Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
11%
C 80%
Factuality
To view factuality data please Upgrade to Premium
